ML
AXSM icon

McAdam LLC’s Axsome Therapeutics AXSM Stock Holding History

McAdam LLC’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,135
Closed -$361K – 522
2026
Q1 		$361K Sell
2,135
-139
-6% -$24K 0.02% 303
2025
Q4 		$415K Buy
2,274
+76
+3% +$10.6K 0.02% 268
2025
Q3 		$267K Buy
2,198
+2
+0.1% +$225 0.01% 330
2025
Q2 		$229K Buy
2,196
+2
+0.1% +$212 0.01% 340
2025
Q1 		$256K Buy
+2,194
New +$250K 0.02% 283
2020
Q1 		– Sell
-2,114
Closed -$219K – 109
2019
Q4 		$219K Buy
+2,114
New +$85.4K 0.05% 81
2018
Q4 		– Sell
-2,000
Closed -$7K – 100
2018
Q3 		$7K Hold
2,000
– – ﹤0.01% 373
2018
Q2 		$6K Buy
+2,000
New +$6.2K ﹤0.01% 368

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

McAdam LLC's AXSM Position: Q2 2026 in Review

McAdam LLC sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 2,135 shares — an estimated $361K sold.

McAdam LLC first reported a position in AXSM in Q2 2018 and held it in 8 quarters. The position peaked at $415K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • McAdam LLC reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • McAdam LLC sold 2,135 Axsome Therapeutics shares in Q2 2026, an estimated $361K.
  • McAdam LLC first reported a position in Axsome Therapeutics in Q2 2018 and held it in 8 quarters.
  • McAdam LLC's Axsome Therapeutics position peaked at $415K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on McAdam LLC's 13F filing for Q2 2026, filed 4 Aug 2026.